ADC Therapeutics ADCT 深 滬
已收盤 08-07 16:00:00 美东时间
1.13
0.000
0.00%
華盛通- 最 高1.17
- 今 開1.08
- 成交量 53.46万股
- 最 低 1.08
- 昨 收 1.13
- 總市值 1.44亿
- 52周最高 4.98
- 市盈率 靜 --
- 換手率 0.42%
- 52周最低 0.7796
- 委 比 60.00%
- 總股本 1.27亿
- 歷史最高 56.59
- 量 比 0.57
- 振 幅 7.96%
- 歷史最低 0.3599
- 每 手 1
- 風險率 1.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
The Russell 2000 opened the second half of 2026 pinned near a record around 3,000, going almost nowhere since the first half closed. Underneath that flat tape, seven small caps ripped 28% or more in just four trading sessions. The index, as tracked by the iShares Russell 2000 ETF (NYSE:IWM), is comi...
07-22 03:52
ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors
ADC Therapeutics Ltd ($ADCT) announced an update on their ongoing clinical stud...
07-21 00:30
ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLONTA In Combination With Bispecific Antibody Glofitamab In Patients With R/R Diffuse Large B-Cell Lymphoma
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug con...
06-30 19:19
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- A...
06-30 19:15
美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
Why Is ADC Therapeutics Stock Falling Thursday?
ADC Therapeutics stock plunges premarket as LOTIS-3 trial shows elevated serious, Grade 5 adverse events despite meeting its primary endpoint.
06-04 20:44
ADC Therapeutics Announces Topline Data From Phase 3 LOTIS-5 Confirmatory Trial Evaluating ZYNLONTA In Combination With Rituximab In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Company to host conference call today at 4:30 p.m. EDTLAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial
06-04 04:13
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
